Copenhagen, Denmark – September 8, 2026 – Novo Nordisk, the Danish pharmaceutical giant renowned for its leadership in diabetes and obesity care, has announced the premature termination of two pivotal Phase III trials for its inflammation-targeting candidate, ziltivekimab. The trials, known as HERMES and ATHENA, were evaluating the Interleukin-6 (IL-6) targeting therapy in patients with heart failure and inflammation. This decision follows a recommendation from an independent data monitoring committee (DMC), which concluded that the drug was unlikely to achieve its primary endpoints, echoing the earlier failure of the Phase III ZEUS trial in July.
n
The move marks a significant recalibration of Novo Nordisk’s strategy in the cardiovascular inflammation space, a therapeutic area it entered with considerable investment. While two major programs are being halted, the company has confirmed its commitment to the ongoing Phase III ARTEMIS trial, which is assessing ziltivekimab’s potential as an acute treatment in the post-heart attack setting. The future of ziltivekimab, a once-monthly subcutaneous injectable, now hinges entirely on the success of this remaining study.
n
Main Facts: A Strategic Retreat in Cardiovascular Inflammation
n
Novo Nordisk’s announcement, initially reported by Endpoints on September 7th and subsequently confirmed by the company to Clinical Trials Arena, details the immediate cessation of the HERMES (NCT05636176) and ATHENA (NCT06200207) trials. These studies were designed to explore ziltivekimab’s efficacy against placebo in patients grappling with heart failure exacerbated by inflammation, a patient population with significant unmet medical needs.
n
The decision to terminate was not made lightly but was based on a comprehensive review by an independent Data Monitoring Committee. This committee, tasked with safeguarding patient safety and ensuring trial integrity, assessed the accumulating data and advised that it was improbable for either HERMES or ATHENA to yield results substantially different from those observed in the earlier ZEUS trial (NCT05021835). The ZEUS trial, which reported its disappointing outcome in July, failed to demonstrate a reduction in major adverse cardiovascular events (MACE) in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and inflammation.
n
For Novo Nordisk, this represents a substantial setback in its efforts to diversify its pipeline beyond its core metabolic franchises. Ziltivekimab was acquired through a significant investment in 2020, positioning it as a key asset in addressing the complex interplay between inflammation and cardiovascular disease. The company’s immediate pivot to focus solely on the ARTEMIS trial underscores a strategic re-evaluation of ziltivekimab’s most promising application, targeting an acute, rather than chronic, inflammatory process in cardiovascular disease.
n
Chronology of Ziltivekimab’s Ambitious Journey
n
The story of ziltivekimab within Novo Nordisk’s portfolio began with an ambitious acquisition and a compelling scientific hypothesis, evolving through various clinical stages before facing its current challenges.
n
The Corvidia Acquisition: A Bold Entry into Inflammation
n
In July 2020, Novo Nordisk made headlines with its strategic move to acquire Corvidia Therapeutics, a Massachusetts-based biotech company, in a deal valued at $725 million upfront, with potential milestone payments reaching up to $2.1 billion. The centerpiece of this acquisition was ziltivekimab, then a promising Phase II candidate. At the time, Novo Nordisk expressed strong confidence that ziltivekimab had the potential to become a first-in-class treatment for a range of cardiovascular diseases driven by inflammation. The acquisition was seen as a bold step by Novo Nordisk to expand its cardiovascular pipeline and leverage its expertise in developing and commercializing chronic disease therapies. The scientific rationale was rooted in the growing understanding of the role of chronic inflammation in the pathogenesis and progression of cardiovascular diseases, offering a new avenue for intervention beyond traditional risk factor management.
n
The ZEUS Trial: Early Promise Meets Clinical Reality
n
Following the acquisition, Novo Nordisk accelerated the development of ziltivekimab into late-stage clinical trials. The ZEUS trial (NCT05021835) emerged as a flagship study, designed to assess the drug’s impact on major adverse cardiovascular events (MACE) in a high-risk population. Patients enrolled in ZEUS suffered from atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and evidence of systemic inflammation. The trial sought to demonstrate that by inhibiting IL-6, ziltivekimab could reduce the incidence of heart attack, stroke, and cardiovascular death – critical outcomes for this vulnerable patient group.
n
However, in July 2026, the pharmaceutical world received news of ZEUS’s failure to meet its primary endpoint. This outcome was a significant blow, raising questions about the efficacy of IL-6 inhibition in broadly reducing MACE in this complex patient population. While specific data details have yet to be fully disclosed, the failure suggested that the anti-inflammatory effect of ziltivekimab, while potentially present, did not translate into a statistically significant reduction in major cardiovascular events as hypothesized.
n
HERMES and ATHENA: Targeting Heart Failure with Inflammation
n
Undeterred by the ZEUS outcome initially, Novo Nordisk continued with its other late-stage programs for ziltivekimab, specifically focusing on heart failure with inflammation. The HERMES (NCT05636176) and ATHENA (NCT06200207) trials were initiated to delve into this distinct patient population.
n
- n
- HERMES was designed to evaluate ziltivekimab’s impact on the time to first occurrence of a composite of heart failure endpoints. These included crucial metrics such as cardiovascular death, heart failure-related hospitalizations, and urgent visits for heart failure. The trial aimed to demonstrate a direct clinical benefit in managing the acute and chronic manifestations of heart failure.
- ATHENA, on the other hand, focused on a broader spectrum of heart failure-specific factors. This included assessing the drug’s potential to influence patients’ quality of life, functional capacity, and other patient-reported outcomes, which are increasingly recognized as vital indicators of treatment success in chronic conditions like heart failure.
n
n
n
Both trials were pitting ziltivekimab against a placebo, maintaining rigorous double-blind, randomized controlled trial designs to ensure scientific validity. The continuation of these trials even after the ZEUS setback highlighted Novo Nordisk’s belief that ziltivekimab might still hold promise in specific cardiovascular contexts, particularly where inflammation plays a more direct and measurable role in disease progression or symptoms.
n
The DMC’s Recommendation and the Present Halt
n
The pivotal moment arrived on September 4th, 2026, when Novo Nordisk informed investigators of the decision to prematurely halt both HERMES and ATHENA. This decision was a direct consequence of a recommendation from the independent Data Monitoring Committee. The DMC, having reviewed the totality of the available data from the ongoing trials, concluded that it was highly unlikely for ziltivekimab to achieve its primary objectives in either HERMES or ATHENA. The shadow of the ZEUS trial’s failure loomed large over this determination, suggesting a consistent pattern of insufficient efficacy across different cardiovascular indications. The committee’s advice, driven by scientific rigor and patient welfare, effectively signaled the end of ziltivekimab’s broad application in chronic cardiovascular inflammation.
n
Scientific Context and Supporting Data: The Inflammation Hypothesis in CVD
n
The development of ziltivekimab was predicated on the "inflammation hypothesis" in cardiovascular disease (CVD), a compelling scientific theory that has garnered significant attention over the past two decades. Understanding this hypothesis and ziltivekimab’s mechanism of action is crucial to appreciating the drug’s initial promise and the challenges it ultimately faced.
n
Ziltivekimab’s Mechanism: Targeting Interleukin-6 (IL-6)
n
Ziltivekimab is a monoclonal antibody designed to specifically target and inhibit Interleukin-6 (IL-6). IL-6 is a pleiotropic cytokine, meaning it has multiple effects on various cell types, playing a crucial role in immune responses, inflammation, and hematopoiesis. In the context of cardiovascular disease, chronic elevated levels of IL-6 are associated with systemic inflammation, endothelial dysfunction, plaque instability, and myocardial remodeling, all of which contribute to the progression of atherosclerosis and heart failure. By blocking IL-6, ziltivekimab aimed to dampen this inflammatory cascade, thereby potentially mitigating the underlying pathology of CVD.
n
The rationale for targeting IL-6 specifically stemmed from preclinical studies and observational data suggesting its significant involvement in inflammatory processes relevant to heart disease. Elevated IL-6 levels are often found in patients with acute coronary syndromes, chronic heart failure, and those at high risk for cardiovascular events.
n
The Broader Inflammation Hypothesis in CVD
n
The idea that inflammation plays a causal role in CVD, not just an associative one, gained significant traction with studies showing that inflammatory biomarkers like high-sensitivity C-reactive protein (hsCRP) are independent predictors of cardiovascular events. This led to the exploration of anti-inflammatory therapies as a novel approach to CVD prevention and treatment.
n
A notable example in this field is the CANTOS trial, which investigated canakinumab, an IL-1β inhibitor, in patients with previous myocardial infarction and elevated hsCRP. CANTOS demonstrated that targeting inflammation with canakinumab could reduce the risk of recurrent cardiovascular events, thereby providing the first definitive proof-of-concept for the inflammation hypothesis in CVD. However, canakinumab also came with an increased risk of fatal infections, highlighting the delicate balance involved in systemic immune modulation.
Trial Design and Specific Endpoints
The designs of the HERMES and ATHENA trials were meticulously crafted to address specific aspects of heart failure and inflammation:
- HERMES (NCT05636176): This trial’s primary endpoint focused on the time to first occurrence of a composite of heart failure-related events, including cardiovascular death, heart failure hospitalizations, or urgent visits requiring intravenous diuretics. These are hard clinical endpoints directly reflecting the severity and progression of heart failure. A positive outcome here would have indicated a tangible benefit in reducing the burden of disease and improving patient survival.
- ATHENA (NCT06200207): This study took a broader approach, examining a range of heart failure-specific factors. While not explicitly detailed in the source, such trials typically include assessments of quality of life using validated questionnaires (e.g., Kansas City Cardiomyopathy Questionnaire – KCCQ), functional capacity (e.g., 6-minute walk test), and other patient-reported outcomes. A successful ATHENA trial would have demonstrated that ziltivekimab could improve the daily lives of patients, beyond just preventing major clinical events.
The distinct endpoints of HERMES and ATHENA reflected an attempt to comprehensively evaluate ziltivekimab’s potential across different facets of heart failure. The hope was that even if the drug didn’t reduce major adverse events across the board (as in ZEUS), it might still offer significant benefits in improving the quality of life or reducing specific heart failure-related events in a more targeted population.
The Role of the Data Monitoring Committee (DMC)
The decision to halt these trials was based on a recommendation from an independent Data Monitoring Committee. A DMC is a critical component of large-scale clinical trials, comprising independent experts (clinicians, statisticians, ethicists) who periodically review accumulating data on efficacy and safety. Their primary responsibilities include:
- Patient Safety: Ensuring that no treatment arm is causing undue harm.
- Trial Integrity: Maintaining the scientific validity of the study.
- Futility Analysis: Determining if a trial is unlikely to achieve its primary objective, even if continued to completion. This is often done to prevent patients from continuing on a treatment that is not beneficial and to conserve resources.
In this instance, the DMC’s recommendation for futility was based on reviewing the "totality of the data," including likely internal efficacy analyses, and explicitly drawing parallels to the failure of the ZEUS trial. This suggests a pattern of insufficient efficacy that, in the committee’s expert opinion, made it highly improbable for HERMES and ATHENA to yield different, positive results. The independence of the DMC ensures that such critical decisions are made based on objective scientific assessment rather than commercial pressures.
Official Responses and Corporate Outlook
Novo Nordisk’s communication regarding the trial terminations has been measured and professional, adhering to standard pharmaceutical industry practices for such significant announcements.
Novo Nordisk’s Official Statement
In its statement to Clinical Trials Arena, Novo Nordisk confirmed that it had informed investigators on September 4th of the decision to prematurely end the HERMES and ATHENA trials. The company reiterated that this decision was made "based on a recommendation from the data monitoring committee who, after reviewing the totality of the data, concluded that it was unlikely for both the HERMES and ATHENA trials to reach a different outcome to the Phase III ZEUS trial, which missed its primary endpoint in July."
This statement clearly attributes the decision to the independent DMC’s expert assessment, underscoring the scientific basis for the halt rather than an internal corporate decision based solely on financial considerations. It also directly links the outcomes of HERMES and ATHENA to the preceding failure of ZEUS, indicating a broader lack of efficacy for ziltivekimab in the chronic cardiovascular inflammation setting.
Patient Follow-Up Commitment
Crucially, Novo Nordisk also confirmed its commitment to patient welfare despite the trial halts: "All patients will be followed through to their three-months follow-up visit as already planned." This ensures that participants in the HERMES and ATHENA trials receive appropriate medical oversight and that any safety signals or long-term effects are monitored, even though the primary treatment phase has concluded. This is a standard ethical practice in clinical research, ensuring continuity of care and data collection for patient safety and future research insights.
Strategic Pivot to ARTEMIS
Amidst the disappointment, Novo Nordisk highlighted its ongoing commitment to the Phase III ARTEMIS trial. A spokesperson told Clinical Trials Arena that this study, which is evaluating ziltivekimab’s potential as an acute treatment in the post-heart attack setting, "will continue as planned." This immediate pivot signals a refined focus for ziltivekimab, concentrating on an indication where the drug’s mechanism of action might be more acutely relevant or impactful. The data readout for ARTEMIS is anticipated in the first half of 2027, providing a clear future milestone for the ziltivekimab program. This strategic shift suggests that Novo Nordisk believes the acute inflammatory response following a heart attack presents a distinct therapeutic window or pathological mechanism where IL-6 inhibition could still prove beneficial, unlike the more chronic, diffuse inflammation seen in the broader heart failure and ASCVD populations.
Implications and Future Outlook
The termination of two major Phase III trials for ziltivekimab carries significant implications for Novo Nordisk, the broader pharmaceutical industry, and the millions of patients affected by cardiovascular diseases.
For Novo Nordisk: Financial Recalibration and R&D Strategy
The most immediate impact on Novo Nordisk will be financial. The upfront payment of $725 million for Corvidia Therapeutics in 2020, along with subsequent R&D expenditures on three Phase III trials, represents a substantial investment. While the exact write-down amounts will depend on accounting specifics, the failure of two pivotal trials implies a significant loss on this particular asset. This could lead to a reassessment of future acquisition strategies, particularly in novel therapeutic areas outside its established metabolic strongholds.
From an R&D perspective, these failures will prompt an internal review of the company’s cardiovascular pipeline and its approach to inflammation targets. While Novo Nordisk has seen unparalleled success with GLP-1 agonists for diabetes and obesity, diversifying into complex areas like cardiovascular inflammation presents unique challenges. The ziltivekimab setbacks highlight the inherent risks of drug development, even for promising candidates backed by strong scientific rationale. The company may need to refine its patient stratification methods or re-evaluate the specific inflammatory pathways it chooses to target in future cardiovascular programs.
Broader Industry Impact: Challenges of Anti-inflammatory Therapies in CVD
The ziltivekimab failures contribute to a growing body of evidence illustrating the complexities of targeting inflammation in cardiovascular disease. While the CANTOS trial provided a glimmer of hope, the mixed results across various anti-inflammatory agents suggest that the "inflammation hypothesis" is more nuanced than initially perceived.
- Target Specificity: Is IL-6 the right target, or are other inflammatory cytokines (e.g., IL-1β, TNF-α) more critical, or do they play different roles in different CVD subtypes?
- Patient Selection: Are current biomarkers like hsCRP sufficient to identify patients who will truly benefit from anti-inflammatory therapies? There’s a strong indication for the need for more precise biomarkers and a deeper understanding of patient heterogeneity in inflammatory profiles.
- Balance of Efficacy and Safety: Systemic anti-inflammatory agents carry the risk of immunosuppression, which can lead to increased infections. Achieving a therapeutic effect without compromising the immune system remains a significant challenge.
These outcomes will likely encourage pharmaceutical companies to adopt more cautious and targeted approaches to anti-inflammatory drug development for CVD, emphasizing precision medicine strategies and a thorough understanding of disease sub-phenotypes.
The ARTEMIS Trial: A Last Hope for Ziltivekimab
All eyes are now on the Phase III ARTEMIS trial. This study represents the last major opportunity for ziltivekimab to prove its worth. The "acute treatment in the post-heart attack setting" distinguishes ARTEMIS from the chronic indications explored in ZEUS, HERMES, and ATHENA.
The rationale here is distinct: an acute myocardial infarction (heart attack) triggers a robust inflammatory response that, while initially protective, can also contribute to myocardial damage, adverse remodeling, and subsequent heart failure. Targeting this acute inflammatory surge with IL-6 inhibition might prevent or mitigate these detrimental effects. This acute setting could offer a more defined therapeutic window and a clearer pathological role for IL-6 compared to chronic, multifaceted inflammatory processes.
A successful outcome in ARTEMIS, with data expected in the first half of 2027, would offer ziltivekimab a niche in the cardiovascular market, potentially reducing the financial sting of the earlier trial failures. However, the stakes are exceptionally high, as a further setback would likely spell the end for ziltivekimab as a viable drug candidate for Novo Nordisk.
For Patients: A Continued Search for Innovation
For the millions of patients living with heart failure and atherosclerotic cardiovascular disease with inflammation, the news is undoubtedly disappointing. These individuals often face a poor prognosis and a significant burden of symptoms, making the search for novel, effective therapies urgent. While existing treatments manage many aspects of CVD, there remain significant unmet needs, particularly for those with persistent inflammation.
The ziltivekimab setbacks underscore the continuous challenge of developing truly innovative cardiovascular drugs. Patients and clinicians will continue to rely on established guidelines and therapies, while the pharmaceutical industry persists in its efforts to unlock new pathways and develop more effective and safer treatments for these complex conditions.
In conclusion, Novo Nordisk’s decision to halt two major ziltivekimab trials marks a significant turning point for the drug and the company’s cardiovascular strategy. While the setbacks are substantial, the unwavering focus on the ARTEMIS trial highlights a strategic adaptation, betting on a more acute and potentially distinct therapeutic application. The coming year will be critical in determining the ultimate fate of ziltivekimab and providing further insights into the intricate relationship between inflammation and cardiovascular disease.
